Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aliskiren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN known ✓ | P00797 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aliskiren SCHEMBL3476540 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3397036 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL2478013 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL29521564 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL455490 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3476537 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13320734 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13351616 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL7965529 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL6854403 | 1.00 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | claimed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-118159281-A | Compounds for the treatment of conditions associated with PCSK9 activity | 默沙东有限责任公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-116917293-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116887831-A | Factor XIa inhibitors | 默沙东有限责任公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116783187-A | Preparation of tetrahydroindazole derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116457346-A | Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-2773351-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| WO-2014099694-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8703976-B2 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | MILAN SOUKUP (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2013066718-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120296100-A1 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | CarboDesign LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| EP-1200390-B1 | PRODUCTION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYLAMIDES | SPEEDEL PHARMA AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7009078-B1 | Production of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-arly-octanoylamides | SPEEDEL PHARMA AG (CH) | 2006-03-07 | — | — | US | disclosed |
| US-20060041169-A1 | PREPARATION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | NODEN PHARMA DAC (IE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041169-A1 | PREPARATION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | AOC3, AOC2, AOC1 | REN 688/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | REN 24/4885 |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | REN 85/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | REN 19/4885 |
| US-20120296100-A1 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | BCKDK, ACSL6, KHK | REN 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.